BMO $IONS Risdiplam approval remains a headline risk for IONS shares,but expect less active switchi | IONS Message Board Posts

Ionis Pharmaceuticals, Inc.

  IONS website

IONS   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  61330 of 61356  at  2/15/2020 10:38:37 AM  by

iyonwin


 In response to msg 61328 by  arthurs1
view thread

Re: BMO $IONS Risdiplam approval remains a headline risk for IONS shares,but expect less active switching from Spinraza at launch, compared to consensus, as historically physicians are less likely to switch out a working therapy.restricted label for Risdi

You don't need to see "active switching from Spinraza" for this drug to be a significant negative for IONS. Just a significant number of new cases choosing this drug over Spinraza would be enough for IONS stock to take a hit IMO.
 
I don't know if that will happen. There are a lot of questions in my mind about this drug but the market reaction indicates that a lot of people think the drug has merit.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 160
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
61331 Re: BMO $IONS Risdiplam approval remains a headline risk for IONS shares,but expect less active switching from Spinraza at launch, compared to consensus, as historically physicians are less likely to switch out a working therapy.restricted label for Risdi arthurs1 1 2/15/2020 4:23:42 PM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...